Loading
Blood and tissue samples collected in cancer trials are the best material for validating new tests, but most sit unused under contracts that make access impossible. A commons would make them available for approved research.
Sponsors and academic trial groups deposit or catalogue residual biospecimens from completed trials (with linked clinical outcomes) in a federated commons with a single access committee, standard consent language for future trials that permits secondary research, and cost-recovery pricing. Access priority goes to biomarker validation studies and to negative-trial samples that can explain why drugs failed. The NCI's cooperative group banks and the EORTC's SPECTA show the model at small scale; the change is universal deposit obligations and one door to knock on.
Shares Proteomics & phosphoproteomics, Companion diagnostics, Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
Shares Proteomics & phosphoproteomics, Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
Shares Proteomics & phosphoproteomics, Companion diagnostics.
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/